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ABSTRACT The rate-limiting step of cholesterol bio-
synthetic pathway is catalyzed by 3-hydroxy-3-methylglu-
taryl coenzyme reductase (HGMR), whose inhibitors,
the statins, widely used in clinical practice to treat
hypercholesterolemia, often cause myopathy, and
rarely rhabdomyolysis. All studies to date are limited to
the definition of statin-induced myotoxicity omitting to
investigate whether and how HMGR inhibition influ-
ences muscle functions. To this end, 3-mo-old male rats
(Rattus norvegicus) were treated for 3 wk with a daily
intraperitoneal injection of simvastatin (1.5 mg/kg/d),
and biochemical, morphological, mechanical, and func-
tional analysis were performed on extensor digitorum
longus (EDL) muscle. Our results show that EDL
muscles from simvastatin-treated rats exhibited re-
duced HMGR activity; a 15% shift from the fastest
myosin heavy-chain (MHC) isoform IIb to the slower
IIa/x; and reduced power output and unloaded short-
ening velocity, by 41 and 23%, respectively, without any
change in isometric force and endurance. Moreover,
simvastatin-treated rats showed a decrease of maximum
speed reached and the latency to fall off the rotaroad
(30%). These results indicate that the molecular
mechanism of the impaired muscle function following
statin treatment could be related to the plasticity of fast
MHC isoform expression.—Trapani, L., Melli, L., Se-
gatto, M., Trezza, V., Campolongo, P., Jozwiak, A.,
Swiezewska, E., Pucillo, L.P., Moreno, S., Fanelli, F.,
Linari, M., Pallottini, V. Effects of myosin heavy chain
(MHC) plasticity induced by HMGCoA-reductase inhi-
bition on skeletal muscle functions. FASEB J. 25,
000–000 (2011). www.fasebj.org
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The main products of the mevalonate (MVA) path-
way—cholesterol, ubiquinone (CoQ), prenyl diphos-
phate, and dolichol—are essential compounds for sur-
vival, proliferation, and differentiation of all mammal
tissues (1, 2). In skeletal muscle, cholesterol is essential
for the propagation of action potentials along the cell
(3). CoQ participates in electron transport during
oxidative phosphorylation in mammalian mitochon-
dria, ensuring the production of ATP needed for
muscle contraction (4). Oligoprenyl groups are neces-
sary for post-translational modification of proteins cru-
cial for cell proliferation and differentiation; among
others, the small Rho GTPases, able to activate Rho-
associated serin/threonine kinase (Rho-kinase) (5).
Lastly, dolichol is needed for N-linked glycoprotein
biosynthesis (6).
The rate-limiting step of the MVA pathway, the
4-electron reduction of 3-hydroxy-3-methylglutaryl co-
enzyme A (HMG CoA) to MVA, is catalyzed by HMG-
CoA reductase (HMGR). Thus, as the central regulator
of cholesterol homeostasis, HMGR became the target
for drugs that control plasma cholesterol levels. The
enzyme is highly regulated; short-term regulation is
achieved by phosphorylation/dephosphorylation reac-
tions exerted by AMP-activated kinase (AMPK) and
protein phosphatase 2A (PP2A), respectively. Long-
term regulation concerns the modulation of HMGR
protein levels by several factors, among others sterol
regulatory element binding protein (SREBP) and insu-
lin-induced genes (Insigs), which can affect enzyme
transcription and degradation as a function of an
intracellular sterol amount and of cholesterol uptake
by low-density lipoprotein receptor (LDLr) (7).
Statins, strong HMGR competitive inhibitors widely
used to treat hypercholesterolemia, besides the benefi-
cial effects on plasma lipid profile, can cause myopathy
characterized by weakness, pain, elevated serum crea-
tine phosphokinase (CK) (2), and to a lesser extent
(0.05%), rhabdomyolysis, a life-threatening condition
(8). Moreover, previous data demonstrate that HMGR
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is crucial for myoblast differentiation to occur (9);
indeed, HMGR inhibition or down-regulation lead to
both the reduction of muscle differentiation markers
[myogenin and fetal myosin heavy chain (f-MHC)] and
of myoblast fusion into multinucleated syncitia (9).
Although these combined findings bring out the
importance of HMGR activity in skeletal muscle physi-
ology, all the studies so far are limited to the definition
of statin-induced myotoxicity, omitting to investigate
whether and how the inhibition of HMGR activity
influences muscle functions. Moreover, epidemiologi-
cal studies show that some patients treated with statins
complain of muscle pain without any increase in
plasma content of muscle damage markers, such as
serum CK (4), which suggests that HMGR inhibition
could impair muscle function without exerting any
muscle toxicity.
Here we studied in vivo the role of HMGR inhibition
by simvastatin on skeletal muscle physiology through
biochemical, morphological, mechanical, and func-
tional approaches.
MATERIALS AND METHODS
Reagents
All chemicals were obtained from commercial sources and of
the highest quality available. Sources not specified were
obtained from Sigma-Aldrich (Milan, Italy).
Animals
Wistar Rattus norvegicus, 3-mo-old male (Harlan Nossan, S.
Pietro al Natisone, Italy), were housed under controlled
temperature (201°C), humidity (5510%), and illumina-
tion (lights on for 12 h daily, from 7 AM to 7 PM). Food and
water were provided ad libitum. The experiments were per-
formed according to the ethical guidelines for the conduct of
animal research (Ministero della Salute, Official Italian Reg-
ulation No. 116/92, Communication to Ministero della Salute
no. 391/121). Rats were divided into 2 groups of 28 animals
each. The first group was treated daily with intraperitoneal
injection of 1.5 mg/kg simvastatin in vehicle [dimethyl sul-
foxide (DMSO), 1 ml/kg] for 3 wk, a dose comparable to the
highest one used in therapies against human hypercholester-
olemia. Control animals received daily an equal volume of
vehicle. At the end of the treatment, rats were anesthetized
with ether in a fume cupboard, and plasma was obtained from
blood collected into EDTA (1 mg/ml blood). Extensor
digitorum longus (EDL) and gastrocnemius muscles of 7
animals/group were dissected and immediately frozen in
liquid nitrogen for subsequent biochemical assays. Eight
animals from each group were used for mechanical analyses;
in particular, after dissection, EDL muscles were mounted in
an experimental trough to analyze the contractile properties.
For immunolocalization studies, EDL muscles from both sides
of 3 animals/group were isolated and fixed by immersion in
phosphate-buffered saline (PBS; pH 7.4) containing 4%
freshly depolymerized paraformaldehyde, overnight at 4°C.
For rotarod motor coordination test and open-field locomo-
tor activity, 10 animals/group were used.
Biochemical analysis
Plasma cholesterol analysis
Plasma cholesterol content of rats was assessed through the
colorimetric CHOD-POD kit (Assel, Rome, Italy) according
to manufacturer’s instructions. Briefly, by the catalysis of
cholesterol esterase and cholesterol oxidase, cholesterol ester
was catalyzed to yield H2O2, which oxidates 4-aminoantipy-
rine with phenol to form a colored dye of quinoneimine. The
absorbancy increase is directly proportional to the concentra-
tion of cholesterol.
Tryglyceride and creatin kinase assays
Plasma triglyceride levels and creatin kinase activity were
measured by standardized commercial methods on a fully
automated system (Modular; Roche, Basel, Switzerland). Tri-
glycerides are hydrolyzed to glycerol by lipoprotein lipase and
oxidized to dihydroxyacetone phosphate and hydrogen per-
oxide, which reacts with Trinder reagent to form a red dye.
The color intensity is directly proportional to triglyceride
concentration. This method is linear between 4 and 1000
mg/dl. Activity of creatin kinase measurement is in accor-
dance with the method recommended by the International
Federation of Clinical Chemistry at 37°C.
HMGR activity
The assay was carried out with the radioisotopic method,
following the production of [14C]-MVA from 3-[14C]- hy-
droxymethylglutaryl coenzyme A (3-[14C]-HMGCoA; specific
activity 57.0 mCi/mmol; GE Healthcare, Little Chalfont, UK).
Microsomes were prepared as described previously (10) from
gastrocnemius. Microsomes were incubated in presence of
cofactors (20 mM glucose-6 phosphate, 20 mM NADP
sodium salt, 1 IU glucose-6 phosphate dehydrogenase, and 5
mM dithiothreitol). The assay, in a final volume of 200 l, was
started by the addition of 10 l (0.088 Ci/11.7 nmol) of
3-[14C]-HMG CoA. The [14C]-MVA produced was isolated by
chromatography on AG1-X8 ion-exchange resin (Bio-Rad
Laboratories, Milan, Italy), and the radioactivity was counted
by a liquid scintillation analyzer (Tri-Carb 2100 TR; Canberra
Packard, Schwadorf, Austria[b]). An internal standard (3-
[3H]-MVA, specific activity 24.0 mCi/mmol; GE Healthcare)
was added to calculate the recovery.
Membrane and lysate preparation
Total membrane and total lysate were obtained as follows: 100
mg skeletal muscle tissue was homogenized in 0.01 M Tris-
HCl, 0.001 M CaCl2, 0.15 M NaCl, and 0.001 M PMSF (pH
7.5). An aliquot of homogenate was collected and used for
lysate preparation. The remaining homogenate was centri-
fuged for 20 min at 10,000 g. The supernatant was centrifuged
at 100,000 g for 45 min, and the pellet was resuspended and
centrifuged again at 100,000 g for 45 min. The pellet was
solubilized in 0.125 M Tris-HCl (pH 6.8) containing 10% SDS
and protease inhibitor cocktail (sample buffer) and trans-
ferred into microtubes. The aliquot of homogenate was
solubilized by sonication in sample buffer and centrifuged for
5 min at 15,600 g, and the supernatant was transferred into
microtubes. Protein concentration was determined by the
method of Lowry et al. (11). All samples were boiled for 3 min
before loading for Western blotting.
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Protein analysis
Protein profiles were analyzed by Western blotting. Western blot
analysis of LDLr and RhoA were performed on total gastrocne-
mius and EDL plasma membranes, respectively, while the anal-
ysis of MHC isoforms, poly(ADP-ribose) polymerase-1 (PARP-1),
AMPK, and Akt were performed on total EDL lysates. Protein
(20 g) from solubilized membranes was resolved by 12% (for
RhoA), 10% (for P-Akt, total Akt, P-AMPK, and total AMPK),
and 7% (for LDLr, MHC isoforms, and PARP-1) SDS-PAGE at
100 V for 60 min. SDS-PAGE for MHC isoforms was performed
at 140 V for 6 h at 4°C. The proteins were subsequently
transferred electrophoretically onto nitrocellulose for 90 min at
100 V. The nitrocellulose membrane was blocked at room
temperature with 5% fat-free milk in Tris-buffered saline (138
mM NaCl, 27 mM KCl, 25 mM Tris–HCl, and 0.05% Tween-20,
pH 6.8), and probed at 4°C overnight with primary antibodies
(RhoA 26C4 and PARP-1 F-2, Santa Cruz Biotechnology, Santa
Cruz, CA, USA; LDLr ab30532, Abcam, Cambridge, UK; fast
MHC MY-32, slow MHC NOQ7.5.4D, Sigma; P-AMPK, total
AMPK, P-Akt, and Akt, Cell Signaling, Danvers, MA, USA)
followed by incubation for 1 h with secondary IgG antibodies
coupled to horseradish peroxidase (Bio-Rad Laboratories, Mi-
lan, Italy). The nitrocellulose membrane was then stripped with
Restore Western blot stripping buffer (Pierce Chemical, Rock-
ford, IL, USA) for 10 min at room temperature and reprobed
with anti-tubulin (-tubulin DM-1A; Sigma) or anti-caveolin
(caveolin-1 N-20; Santa Cruz Biotechnology) antibodies. Bound
antibodies were visualized using enhanced chemoluminescence
detection (GE Healthcare). All images derived from Western
blotting were analyzed with ImageJ (National Institutes of
Health, Bethesda, MD, USA) software for Windows. Each re-
ported value was derived from the ratio between arbitrary units
obtained by the protein band and the respective tubulin or
caveolin band (chosen as housekeeping proteins).
Lipid extraction
EDL muscle (100 mg) was homogenized in NaCl (150 mM;
1:9, w/v); 6 nmol coenzyme Q6 (CoQ6), 600 l water, 4 ml
methanol, and 4 ml chloroform were added to homogenate.
CoQ6 was added as internal standard to calculate the recovery.
The samples were incubated for 30 min at 37°C. Then, 800 l
NaCl 150mM and 2 ml chloroform were added, and 2 phases
were obtained. The lower phase was evaporated with a stream of
nitrogen. Samples were dissolved in 0.5 ml chloroform and then
divided into halves. The samples used to measure CoQ9 amount
were dissolved in 50 l isopropanol:ethanol (1:1, v/v); the
samples employed to estimate cholesterol and dolichol levels
were hydrolyzed in 0.5 ml 15% KOH in ethanol:water (95:5, v/v)
for 60 min at 95°C. Then the organic phase was extracted with
0.5 ml of water and 1 ml of hexane. The upper phase was
collected and evaporated with a stream of nitrogen, then dis-
solved in 50 l isopropanol:ethanol (1:1, v/v).
HPLC-UV analysis of polyisoprenoids
Lipids were analyzed according to previously described pro-
tocol (12) with modifications. Briefly, two parallel runs, one
for CoQ9 and another for cholesterol, were performed on a
4.6-  75-mm Zorbax XDB-C18 (3.5 m) reversed-phase
column (Agilent, Santa Clara, CA, USA) using a Waters
dual-pump apparatus, a Waters gradient programmer, and a
Waters photodiode array detector (spectrum range: 210–400
nm; Waters Corp., Milford, MA, USA). For elution, a combi-
nation of convex gradients (Waters No. 5, from 0 to 75% B for
the initial 20 min and linear, from 75 to 100% B during the
following 10 min) was used; in the last 5 min, reequilibration
back to 0% B was performed, where solvent A was methanol:
water (9:1, v/v), and solvent B was methanol:propan-2-ol/
hexane (2:1:1, v/v/v). The solvent flow rate was 1.5 ml/min.
HPLC solvents were obtained from POCh (Gliwice, Poland).
The chain length and identity of lipids were confirmed by
applying following standards: CoQ6, CoQ10, and cholesterol.
CoQ10 and cholesterol were purchased from Sigma-Aldrich;
CoQ6 was from the Collection of Polyprenols (Institute of
Biochemistry and Biophysics, PAS, Warsaw, Poland).
Morphological analysis
Fixed EDL muscles were dehydrated in graded ethanol,
transferred to Bioclear (BioOptica, Milan, Italy) and then to
a 1:1 mixture of Bioclear and paraffin, and finally embedded
in paraffin. Transverse, 7-m-thick sections were cut by a
microtome and collected on Vectabond precoated slides
(Vector, Burlingame, CA, USA). Sections were deparaf-
finized, rehydrated, and submitted to antigen retrieval, using
antigen unmasking solution (Vector). After cooling, slides
were transferred to PBS containing 3% hydrogen peroxide,
for 5 min, in the dark, then to PBS with 0.2% Triton X-100
and 3% bovine serum albumin (BSA), for 1 h at room
temperature. Sections were incubated overnight at 4°C with
either of the following mouse polyclonal antibodies, diluted
in PBS containing 0.1% Triton X-100 and 1.5% BSA: fast
MHC MY-32 1:1000, slow MHC NOQ7.5.4D 1:5000 (Sigma).
In control sections, the primary antibody was omitted. Slides
were then incubated for 1 h at room temperature with
biotinylated goat anti-rabbit IgG (Vector), diluted 1:200 in
PBS containing 1% normal goat serum (Vector). Immuno-
complexes were revealed by means of an avidin biotin system
(Vectastain Elite ABC kit, Vector), using 3,3-diamino-benzi-
dine (DAB Substrate kit for peroxidase; Vector), as the
chromogen. Sections were counterstained with hematoxylin,
then dehydrated and mounted with Eukitt (Kindler GmbH &
Co., Freiburg, Germany). Slides were observed under an
Olympus BX 51 microscope (Olympus, Tokyo, Japan)
equipped with a Leica DFC 420 camera (Leica Microsystems,
Wetzlar, Germany); electronic images were captured by a
Leica Application Suite system, and composed in an Adobe
Photoshop CS2 format (Adobe Systems, San Jose, CA, USA).
Mechanical analysis
EDL muscle was dissected by using scissors and forceps under
a stereomicroscope (Stemi SV11; Carl Zeiss MicroImaging,
Oberkochen, Germany) and mounted horizontally, between
the lever of a motor/force transducer system (305C, Aurora
Scientific Inc., Aurora, ON, Canada) and a lever carried by a
micromanipulator, in a trough, containing physiological so-
lution (Krebs-Henseleit solution, composition, in mM: 119
NaCl, 4.7 KCl, 2.5 CaCl2, 1.0 MgSO4, 25 NaHCO3, 1.2
KH2PO4, and 1.1 glucose) gassed with carbogen (95% O2 and
5% CO2, pH7.4). The muscle was straightened just above its
slack length by means of the micromanipulator. The trough
was sealed with a Perspex cover and mounted vertically on the
stage with the motor/force transducer system on top. The
solution was continuously saturated with carbogen during the
experiment. Room temperature was in the range 20–22°C.
Trains of stimuli of alternate polarity to elicit fused tetani
(frequency 70–80 Hz) were delivered by means of two
platinum wire electrodes running parallel to the muscle, 1 cm
apart. The intensity of the stimuli was increased until the
isometric plateau force reached a maximum constant value
T0 (indicating that all the cells in the muscle were activated).
The muscle length was finely adjusted further by means of the
micromanipulator to obtain the maximum isometric force,
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corresponding to the plateau of the force-length relation. To
compare isometric force among muscles, the isometric pla-
teau force was normalized by the wet weight of the muscle,
measured at the end of each experiment with an electrobal-
ance (CP124S; Sartorius, Goettingen, Germany). The force-
velocity relation was determined by measuring the velocity of
steady shortening V after a drop in force from the isometric
value T0 to a preset value TT0. The force-velocity points
were fitted to the Hill hyperbolic equation (Eq. 1):
	T  a)  (V  b) 
 (V0  b)  a (1)
where a, b, and V0 (the unloaded shortening velocity) are the
regression parameters.
To investigate the effects of simvastatin on muscle endurance, a
fatiguing protocol was used. EDL muscle was given a 400-ms fused
tetanus every 3 s over a period of 150 s. The muscle was then
allowed to recover for a period of 40 min, during which force
recovery was monitored with a tetanus every 5 min. Force, length
change, and stimulus were recorded with a multifunction I/O
board (PCI-6110E; National Instruments, Austin, TX, USA) at
0.5-ms sampling rate. A program written in LabVIEW (National
Instruments) was used for signal recording and analysis.
Functional analysis
Rotarod motor coordination test
To assess any effect of simvastatin on motor coordination and
balance, rats were tested in an automated accelerating ro-
tarod apparatus (Biological Research Apparatus; Ugo Basile,
Varese, Italy; ref. 13). The apparatus consisted of 7-cm-
diameter plastic drums machined with grooves to improve
grip, that could be set on accelerating speed (4, 10, 12, 15, 19,
22, 26, 29 34 and 40 rpm, 30 s at each speed).
Before testing, the rats were trained for 2 d, applying the
following schedule (14): the first day, the rats were trained for
3 min with an unlimited number of trials on the rotarod,
followed by 4 trials of maximum 60 s with a 30 s intertrial
interval; the second day, the rats were placed on the rotarod
at accelerating speed for a maximum of 300 s. Testing was
performed after 21 d of treatment with simvastatin; each rat
was individually placed on the rotarod at accelerating speed
for a maximum of 300 s, and the latency to fall off the rotarod
and the maximum speed reached within this time period
were recorded. Immediately after each session, the apparatus
was thoroughly cleaned with cotton pads wetted with 70%
ethanol;water solution and dried. Rats were allowed to habit-
uate to the experimental room for 60 min before both
training and testing. Training and testing were performed
between 10:00 AM and 1:00 PM.
Open-field locomotor activity
The day after rotarod testing, the rats were tested for horizontal
locomotor activity. The animals were transferred from the
holding room to the experimental room, where they were
allowed to habituate for 60 min. Testing was conducted under
dim light between 10:00 AM and 1:00 PM. The test started by
placing each animal in the center of an open-field arena (8080
cm) made of gray Plexiglas. Behavior was videorecorded for 10
min using a digital video camera for subsequent analysis. All
scores were assigned by the same observer, who was unaware of
animal treatment. Immediately after each session, the apparatus
was thoroughly cleaned with cotton pads wetted with 70%
ethanol:water solution and dried. The following behavioral
parameters were scored: number of crossings (crossing with
both forepaws the lines in which the floor of the arena was
subdivided on the monitor), time spent near the walls (periph-
ery), time spent in the central part of the arena, and frequency
and duration of rearing (standing with the body inclined
vertically, forequarters raised), wall-rearing (standing on the
hind-limbs and touching the walls of the apparatus with the
forelimbs), and grooming (rubbing the body with paws or
mouth and rubbing the head with paws).
Statistical analysis
Data are expressed as means  sd. The difference of parameters
was statistically tested for significance with unpaired Student’s t test.
Values of P  0.05 were considered to indicate a significant
difference. Statistical analysis was performed using GraphPad In-
stat3 (GraphPad, Inc., La Jolla, CA, USA) and SigmaPlot (Systat
Software Inc., San Jose, CA, USA) for Windows.
RESULTS
Simvastatin efficacy and tolerance
Simvastatin efficacy in lowering plasma LDL-cholesterol
(15) and triglycerides (16) by hepatic LDLr up-regulation
(17) was verified by checking rat plasma cholesterol and
triglyceride content (Table 1). As expected, both the
metabolic parameters decreased significantly with the
following treatment, by 30% and 53%, respectively. Nev-
ertheless, simvastatin treatment did not modify animal
weight, even though the weight of treated animals was
slightly lower than that of rats receiving vehicle (Fig. 1A).
Moreover, simvastatin treatment lowered HMGR activity
in the gastrocnemius muscle by 20% (Fig. 1B). Evidence
for drug efficacy on skeletal muscle was also given by the
increased levels of LDLr protein in the gastrocnemius
muscle of treated rats (Fig. 1C), in good agreement with
the rise of LDLr mRNA observed previously (18).
Once simvastatin efficacy on skeletal muscle was
ascertained, our attention focused on the effects ex-
erted by HMGR inhibition on EDL muscle, which
consists mainly of fast and glycolitic fibers, given that
the glycolitic fibers appear to be the most susceptible to
statin side effects (19). Thus, the levels of HMGR end
products involved in skeletal muscle contraction, such
as CoQ9 (4), cholesterol (3), and a prelynated protein
TABLE 1. Effect of simvastatin on metabolism of treated and control rats
Component Vehicle Simvastatin, 1.5 mg/kg P
Cholesterol (mg/dl plasma) 82.35  9.45 57.52  9.22 0.01
Triglycerides (mg/dl plasma) 189.6  37.71 88.86  30.48 0.001
Seven rats contributed to each value. Statistical analysis was done by unpaired t test.
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(RhoA) (5, 20), were assessed. As shown in Table 2, no
significant differences were detected in EDL muscles of
simvastatin-treated rats either in cholesterol or in CoQ9
content. In addition, as shown in Fig. 2A, the translo-
cation of RhoA on EDL plasma membrane and its
consequent activation (21) did not differ in simvastatin-
treated animals when compared to controls.
Effects of simvastatin treatment on muscular damage
To ascertain whether the pharmacological treatment
could have caused possible muscle damage, as de-
scribed previously (2, 8), plasma CKs (22), and muscle
cleaved PARP-1 protein levels, markers for muscle fiber
necrosis and apoptosis, respectively, were checked (Fig.
2B, C). Both CK and PARP-1 protein levels were not
increased in simvastatin treated rats with respect to the
control showing the absence of muscle fiber necrosis
and/or apoptosis.
MHC isoform determination
Previous data demonstrated that HMGR inhibition by
mevinolin (3 M) can modulate fetal MHC expression
in L6 myoblasts (9). This finding prompted us to assess
whether a putative modification of MHC isoform ex-
pression could occur in EDL muscle after simvastatin
treatment. Morphological observation of sections from
simvastatin-treated EDL muscles indicated unaltered
cytoarchitecture, compared to controls. The immuno-
histochemical localization of fast and slow MHC iso-
forms on EDL muscles from simvastatin-treated and
control rats showed similar, though not identical, dis-
tribution of positive fibers in either conditions (Fig. 3).
Muscle cells immunoreactive to anti-fast MHC isoform
represented the large majority of fibers in sections from
both treated and untreated muscles (Fig. 3A, B). How-
ever, the occurrence of negative fibers, most probably
corresponding to slow MHC isoform-expressing cells,
appeared to be increased after treatment. Accordingly,
simvastatin seemed to produce an increased frequency
of slow MHC immunoreactive fibers, as shown in Fig.
3C, D, but the data are not statistically significant.
Moreover, an enhanced immunodensity of the positive
cells was detected after the pharmacological treatment,
suggesting that the expression of slow MHC isoform
could be higher under this condition.
Immunohistochemical analysis suggests that a change
in fiber structure could occur. To better ascertain
putative differences in MHC isoform expression, West-
ern blot analysis was performed. As observed in Fig. 4A,
no differences were detected in the slow MHC isoform
expression. The apparent discrepancy between the data
obtained by immunohistochemistry and those obtained
by Western blot can be explained if the low percentage
of EDL fibers expressing the slow MHC isoform is
considered. Thus, Western blot analysis is not sensitive
enough to detect the difference highlighted through
morphological observation. Electrophoresis separation
shows a shift of the fast MHC isoforms, from the fastest
TABLE 2. Effect of simvastatin treatment on HMGR end products of the mevalonate pathway
End product Vehicle Simvastatin, 1.5 mg/kg P
Cholesterol (g/g tissue) 92.10  10.94 106.56  10.87 0.22
CoQ9 (g/g tissue) 19.09  8.04 17.43  5.63 0.84
Seven muscles contributed to each value. Statistical analysis was done by unpaired t test.
Figure 1. Efficacy and tolerance of simvastatin. A) Growth curve of rats treated with
simvastatin (1.5 mg/kg) or vehicle alone. Rats were weighed every 4 d; n
 7 animals/group.
B) HMGR activity in microsomes prepared from skeletal muscle (gastrocnemius) of rats
treated with simvastatin or vehicle alone. Activity of the enzyme is expressed as [14C]-MVA
production (pmol/min/mg protein) from 3-[14C]-HMG CoA added to the samples. C) Representative Western blot (bottom
panel) and densitometric analysis (top panel) of LDLr protein levels. The 3 bands (110, 130, 160 kDa) detected represent the
different and increasing glycosylation state of the LDLr. Protein levels were normalized to -tubulin content. Data are
expressed as arbitrary units; n 
 7 animals/group. Values are presented as means  sd. **P  0.01, ***P  0.001; Student’s
t test.
5SIMVASTATIN AFFECTS MUSCLE CONTRACTION
MHC IIb to the slower MHC IIa/x (Fig. 4B) in the
simvastatin-treated rats with respect to control. In the
control group, EDL muscle contained 85% of MHC
IIb isoform, with a small (15%) amount of MHC IIa/x
isoforms, while EDL muscle of simvastatin-treated rats
contained 70% of MHC IIb isoform, and 30% of
MHC IIa/x isoforms.
Statin treatment can interfere with the intracellular
pathways responsible for MHC isoform switch; thus, the
activity of Akt and of AMPK, whose phosphorylation
states were demonstrated to be modified by statins (23,
24), was analyzed. In particular, Akt and AMPK are
negative and positive regulators, respectively, of perox-
isome proliferator-activated receptor- coactivator 1-
(PGC-1), which plays a central role in muscle plasticity
(25). Figure 5 shows that no changes in the phosphor-
ylation levels of these two kinases are observable after
simvastatin treatment.
Figure 2. Biochemical measurements on simvastatin-treated and control rats. A) RhoA levels in EDL membranes of
simvastatin-treated and control rats. Representative Western blot (bottom panel) and densitometric analysis (top panel) of
RhoA detected in total membranes prepared from EDL muscle of rats treated with simvastatin or vehicle alone. Protein levels
were normalized to caveolin content. Data are expressed as arbitrary units; n 
 7 animals/group. B) Creatine kinase levels
(U/L) detected from plasma of rats treated with simvastatin or vehicle alone. C) Representative Western blot (bottom panel)
and densitometric analysis (top panel) of full-length (116 kDa) and cleaved (89 kDa) PARP-1 detected in total lysates obtained
from EDL muscle of rats treated with simvastatin or vehicle alone. Protein levels were normalized to -tubulin content. Data are
expressed as arbitrary units; n 
 7 animals/group. Values are presented as means  sd.
Figure 3. Immunohistochemical localization of
fast and slow MHC isoforms in EDL muscle
sections from simvastatin-treated and control
rats. A, B) Fast MHC isoform immunohisto-
chemistry in control (A) and simvastatin-treated
(B) EDL muscle sections. Positive fibers are
widely distributed in the tissue, under both
conditions. However, immunonegative cells (ar-
rows) are more numerous in simvastatin-treated
muscle, compared to control. C, D) Slow MHC
isoform immunohistochemistry in control (C)
and simvastatin-treated (D) EDL muscle sec-
tions. Scattered, positive fibers are observed in
the tissue, under both conditions. However,
higher numbers of positive cells (arrows), show-
ing intense immunoreactivity, are present in
treated muscle, compared to control. Scale
bars 
 100 m.
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Effect of simvastatin treatment on muscle function
To understand whether the observed shift from the
fastest MHC IIb isoform to the slower MHC IIa/x
isoforms could affect the mechanical properties of EDL
muscle, the effects of simvastatin treatment on the
contractile properties of fast skeletal muscle were eval-
uated. In particular, the maximum steady force elicited
by the isometric tetanus T0, twitch-to-tetanus ratio t/T0,
time to attain half of the isometric tetanic plateau force
t1/2, and force-velocity relation (Table 3 and Fig. 6)
were recorded. T0 was normalized by the different mass
of muscles by mean of the procedure described in Mate-
rials and Methods. Simvastatin treatment, with respect to
control, reduced T0 and t/T0 by 23 and 22%, respectively
(but the difference is not statistically significant; Table 3);
significantly increased t1/2 by 25% (Table 3); and reduced
the shortening velocity at any load below T0 (Fig. 6C and
Table 3). Consequently, the power, calculated as the
product T  V, was significantly reduced in simvastatin-
treated rats (Fig. 6D). At the load for the maximum
power, 0.3 T0, the power (Wmax) was 41% lower in
simvastatin-treated than in control rats (Table 3). The
unloaded shortening velocity V0, estimated as parameter
of the Hill hyperbolic equation (Eq. 1), was 23% lower in
simvastatin-treated than in control rats (Table 3). To
investigate whether simvastatin treatment affects not
only power but also endurance, EDL muscles were
subjected to a fatigue protocol (see Materials and
Methods). Results showed no difference in the time
course of isometric force reduction to get 40% of the
prefatigue value (Fig. 7), indicating that endurance
performance is not affected by simvastatin treatment.
Also, the time course of force recovery from fatigue,
over 40 min from the end of the fatigue protocol,
which allows isometric force to recover 30% of
force decay in control, showed no effect of simvasta-
tin treatment (ascending part of the curves in Fig. 7).
Rotarod motor coordination and open-field
locomotor activity tests
To assess further whether the effects of simvastatin on
skeletal muscle could result in functional impairments,
we tested the effect of this treatment regimen on motor
coordination and locomotor activity in rats. Treatment
with simvastatin impaired performance in the rotarod
test. Indeed, simvastatin-treated rats showed reduced
latency to fall off the rotarod and reduced maximum
speed reached during test compared to vehicle-treated
animals (Fig. 8). Simvastatin-treated rats did not differ
from vehicle-treated rats for any parameter measured
in the open-field test (number of crossings, Fig. 9A;
Figure 4. Slow and fast MHC protein levels in EDL muscle of simvastatin-treated and control rats. A) Typical Western blot (right
panel) and densitometric analysis (left panel) of slow MHC detected in total lysates prepared from EDL muscle of rats treated
with simvastatin or vehicle alone. B) Representative Western blot (right panel) and densitometric analysis (left panel) of fast
MHC detected in total lysates prepared from EDL muscle of rats treated with simvastatin or vehicle alone. Protein levels were
normalized to -tubulin content. Data are expressed as arbitrary units; n 
 7 animals/group. Values are presented as means 
sd. *P  0.05; Student’s t test.
Figure 5. P-Akt and P-AMPK protein levels of simvastatin-treated and control rats. A) Typical Western blot (right panel) and
densitometric analysis (left panel) of P-Akt detected in total lysates prepared from EDL muscle of rats treated with simvastatin
or vehicle alone. B) Typical Western blot (right panel) and densitometric analysis (left panel) of P-AMPK detected in total lysates
prepared from EDL muscle of rats treated with simvastatin or vehicle alone. Protein levels were normalized to -tubulin content.
Data are expressed as arbitrary units; n 
 7 animals/group. Values are presented as means  sd.
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time in periphery, Fig. 9B; time in center, Fig. 8C; data
not shown for frequency and duration of wall-rearing,
rearing, and grooming).
DISCUSSION
In the current study, we investigated the role of HMGR
inhibition by simvastatin on skeletal muscle physiology.
This lipophilic HMGR inhibitor was chosen because the
lipophilic statins are generally taken up much more
widely into a broad range of tissues and cells by diffusion
compared with hydrophilic statins (26). Chronic treat-
ment with simvastatin (1.5 mg/kg) inhibits HMGR activity
in skeletal muscle to a similar extent as in the liver, where
the effect of statins is well documented (19); induces a
shift of MHC isoforms toward a slower phenotype; re-
duces the power output and the unloaded shortening
velocity of EDL muscle without a significant reduction in
isometric force and resistance to fatigue; and induces
functional impairment, i.e., reduction in the latency to fall
off the rotarod.
Because power involves not just force production but
also the speed at which the force is produced, deficits in
muscle power can be related to impairment in movement
TABLE 3. Effect of simvastatin treatment on mechanical parameters during isometric contraction
and isotonic shortening of EDL muscle
Parameter Vehicle Simvastatin, 1.5 mg/kg P
Isometric contraction
L0 (cm) 2.96  0.06 2.90  0.17 0.56
w (g) 0.157  0.020 0.164  0.015 0.85
CSA (cm2) 0.110  0.013 0.134  0.021 0.88
T0 (N/g) 13.49  1.25 10.33  5.26 0.21
t/T0 0.325  0.043 0.254  0.019 0.06
t1/2 (ms) 22.9  3.5 28.7  6.7 0.01
Isotonic shortening
V0 (L0/s) 3.87  0.13 2.98  0.14 0.01
a/T0 2.78  0.31 2.42  0.40 0.47
b (L0/s) 2.14  0.29 2.00  0.37 0.77
Wmax (mW/g) 134.7  11.3 79.7  3.4 0.01
Four muscles contributed to each value. Statistical analysis was done by unpaired t test. Isometric
contraction parameters: L0 , muscle length at the plateau of the force-length relation; w, muscle wet weight;
CSA, cross-sectional area of muscle, calculated using the relation CSA 
 w/(L0k) (cm
2), where  is the
density of the muscle (1.056 g/cm3) and k is a constant (0.40 for EDL muscle; ref. 39); T0 , isometric force;
t/T0 , twitch-to-tetanus ratio; t1/2, time to attain half of the tetanic isometric force. Isotonic shortening
parameters: V0 , a/T0 , and b are regression parameters of the Hill hyperbolic equation (Eq. 1) fitted to the
pooled data for simvastatin-treated rats and control, with statistical analysis by Student’s t test of difference of
means; Wmax, maximum power, obtained with a load 1/3 the isometric force.
Figure 6. Mechanical measurements on EDL muscle of simvastatin-treated and control rats.
A) Time course of force (top trace) and length (bottom trace) changes. B) Length changes
during a series of isotonic contractions against different loads. Muscle length, 3.0 cm; wet
weight, 144 mg.; cross-sectional area (calculated from the wet weight), 0.114 cm2; tempera-
ture, 21.8°C. C) Force-velocity (T-V) relation in control (open circles) and simvastatin-treated
rats (solid circles). Lines are the Hill hyperbolic equation interpolated on the pooled data for
control (continuous line) and treated (dashed line) rats. D) Power-force relations calculated
from the same data as in panel C. Lines are calculated from the Hill’s equation fitted to the
T-V data. Symbols and lines, same code as in panel C. Data in panels C and D are pooled from
4 experiments on EDL muscle both in control and simvastatin-treated rats.
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and locomotion (27, 28). Biochemical analysis shows that
simvastatin treatment, by means of the shift toward a
slower MHC isoform phenotype, reduces EDL muscle
functions without exerting any muscle damage, in agree-
ment with the lack of evidence for reduction in isometric
force.
The drug efficacy on skeletal muscle tissue was
ascertained by determining HMGR activity and LDLr
protein levels. In agreement with previous studies in
hepatocytes, simvastatin inhibits HMGR activity and
increases the expression of LDLr (19). The putative
myotoxic effects of the drug, whose underlying mech-
anisms are still debated, were excluded by the analysis
of muscle damage markers. It is known that statin
administration can induce muscle fiber necrosis, with
release of cellular constituents such as CK into the
bloodstream (2), and a caspase-dependent apoptotic
cascade leading to the PARP-1 cleavage (29). Any
significant increase of plasma CK and cleaved PARP-1
protein levels in simvastatin-treated rats was found,
indicating that, in agreement with the lack of evidence
for reduction in isometric force, the reduced muscle
function is not related to muscle fiber loss due to
apoptosis or necrosis. The absence of muscle damage
could be explained by the lower dose of simvastatin
used in our study, 1.5 mg/kg (comparable to the
highest dose used to treat hypercholesterolemia in the
clinical practice), with respect to the doses used in
previous studies where muscle damages were described
(30). In fact, the maximum simvastatin dose adminis-
tered in clinical practice is 80 mg/d, corresponding, on
average, to 1.14 mg/kg/d; since the metabolism rate of
rats is higher than that of humans, the dose adminis-
tered to the animals was slightly increased. We also
excluded that the impairment of EDL muscle function
was due to modified levels of HMGR end products
directly involved in muscle contraction; neither choles-
terol nor CoQ9 changed significantly in treated ani-
mals. However, this result cannot rule out a modulation
of HMGR main end products by simvastatin, since only
50% of the body CoQ9 is derived from endogenous
synthesis through the MVA pathway, and the remaining
50% is thought to be obtained through fat ingestion (4)
and carried mainly by LDL in the circulation (12).
Thus, like cholesterol, putative CoQ9 depletion due to
enzyme inhibition by simvastatin could have been re-
stored within the cells and, in turn, within the tissues by
an enhanced LDLr-mediated uptake, as suggested by
the increased LDLr protein expression. Furthermore, the
levels of RhoA were evaluated both because the post-transla-
tional modification with a prenyl group (an HMGR prod-
uct) is necessary for its membrane association and conse-
quent activation, and because RhoA can activate Rho-kinase,
responsible for MLC phosphorylation and, in turn, involved
in the regulation of muscle contraction. Nevertheless, RhoA
activation state did not change in either animal group.
Morphological but overall biochemical analysis show a
change of sarcomeric proteins belonging to the contrac-
tile machinery of the muscle toward a slower phenotype,
especially in the MHC composition of the fibers within
the muscle, which leads to the reduced muscle function
(31, 32). Specifically, simvastatin treatment induces a shift
from the fastest MHC IIb isoform to the slower MHC
IIa/x isoforms. The amount of reduction of V0 (23%),
Wmax (41%), and t1/2 (25%), as well as the lack of
significant change in T0, are in qualitatively good agree-
ment with the changes of these parameters described in
muscles and in fully Ca2-activated skinned fibers from
fast skeletal muscles of mammalians containing different
MHC isoforms (31–35). In particular, fast fibers from rats
containing pure MHC IIa isoform have V0 30% lower
than those containing MHC IIx isoform, and the latter
have V0 20% lower than fibers containing MHC IIb
isoform, while the maximum power in fibers containing
MHC IIa/x isoforms is 30–60% lower than in fibers
containing MHC IIb isoform (33). Moreover, the endur-
ance of EDL muscle, determined by a fatigue protocol, is
not affected by simvastatin.
The simvastatin-induced impairment of muscle per-
formance was also supported by an in vivo functional
test. These changes resulted in reduced maximum
speed reached and reduced latency to fall off the
accelerating rotarod in the absence of general impair-
Figure 8. Effects of simvastatin in the rotarod test. Simvastatin-
treated rats showed reduced latency to fall off the rotarod
(t
3.35, df
17, P0.01; A) and reduced maximum speed
reached during the test (t
3.48, df
17, P0.01; B). n 

10/group. **P  0.01; Student’s t test.
Figure 7. Effects of simvastatin on muscle endurance.
Changes in isometric force on EDL muscle in simvastatin-
treated (solid circles) and control rats (open circles) during
fatigue and recovery. EDL muscles were subjected to a fatigue
protocol consisting of a 400-ms, 100-Hz tetanus every 3 s for
150 s. Descending part of the curve shows the decline in
isometric force. Ascending part of the curve shows the partial
recovery of isometric force up to 40 min from the end of the
fatigue protocol. n 
 4/group. Data are means  sd.
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ments in basal locomotor activity, as measured in the
open-field test. Thus, simvastatin-treated rats showed
normal coordination and were still able to run on the
rotarod at low speeds but, compared to vehicle-treated
animals, could not run the rod at high speeds.
Our results indicate that the simvastatin-induced
impairment of muscle function is not related either to
changes in Akt and AMPK phosphorylation or to
changes in HMGR end products directly involved in
muscle contraction, suggesting that a putative modifi-
cation of other MVA pathway downstream compounds,
such as prenylated proteins (i.e., Cdc42, Ras, Rac) not
evaluated in this work could be at the root of the
observed phenomena (Fig. 10).
Further investigations must define the molecular
mechanisms responsible for the fast MHC isoform
plasticity. This work establishes that a shift in the fast
MHC isoforms is involved in muscle contraction impair-
ment following statin treatment. The observed fast
MHC isoform shift could be responsible for the re-
duced muscle activity, at least in fast muscle, and
functional impairment described in statin-treated pa-
Figure 9. Effects of simvastatin in the open-field test. Simvastatin-treated rats did not differ from vehicle-treated rats in the
number of crossings (t
0.67, df
17, n.s.; A) and in the time spent both in periphery (t
0.51, df
17, n.s.; B) and in center
(t
0.53, df
17, n.s.; C). Moreover, simvastatin- and vehicle-treated rats did not differ in frequency and duration of
wall-rearing, rearing, and grooming (data not shown); n 
 10/group.
Figure 10. Possible mechanisms responsible for the shift of the fast MHC isofoms in EDL muscle fibers. Simvastatin competitively
inhibits the enzyme HMGR (37); can increase the intracellular Ca2 concentration (38), which, in turn, causes an increase of
AMPK activity (23); and can suppress Akt phosphorylation. Both the activation of AMPK and the suppression of Akt
phosphorylation positively modulate PGC-1, which drives a coordinated conversion to fibers having characteristics of oxidative
type I, IIa, and IIx fibers (25). The lack of any modification in both Akt and AMPK phosphorylation and the absence of changes
in HMGR main end products (cholesterol, CoQ9, RhoA) found here, exclude their involvement in MHC shift to slower
phenotype in our experimental model. The shift could be ascribable to other prenylated proteins involved in intracellular signal
transduction pathway (dotted line in the scheme).
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tients (4, 36). This finding suggests that alternative
pharmacological approaches should be considered in
the management of hypercholesterolemia.
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